At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
Topotecan +1 moredrug
Likely dose
Topotecan 4mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Topotecan and carboplatin for Carcinoma, Small Cell. Completed, enrolled 61 participants across 16 sites.
Detailed Summary
This proposed phase II trial will investigate the combination of topotecan/carboplatin in the first-line treatment of patients with extensive-stage SCLC. Topotecan/platinum regimens are emerging as common treatments for patients with extensive-stage disease. This trial will be one of the first clinical trials to evaluate a combination of weekly topotecan and carboplatin in the first-line treatment of extensive-stage SCLC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Small Cell
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedMar 2006
Primary CompletionApr 2009
Study CompletionNov 2009
TodayJul 2026
First PostedMar 22, 2006
Enrollment StartMar 1, 2006
Primary CompletionApr 1, 2009
Study CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.3 years ago
Interventions
Topotecandrug
Topotecan 4mg/m2 IV on days 1, 8.
carboplatindrug
Carboplatin AUC=5 IV day 1 only .